Teduglutide (Revestive®)
Teduglutide (Revestive®) was added to the High Tech Arrangement on 1 January 2021. A Managed Access Protocol is in place for teduglutide. This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of teduglutide under the High Tech Arrangement.
The prescribing of teduglutide (Revestive®) under the High Tech Arrangement is confined to designated clinicians who have agreed to the terms of the HSE-Managed Access Protocol and have been approved by the HSE-Medicines Management Programme. The clinician must submit an application for individual reimbursement approval for each patient. Applications for individual reimbursement approval will only be considered from approved clinicians.
A copy of the HSE-Managed Access Protocol for teduglutide (Revestive®) and the application form for individual reimbursement approval can be found in the Related Files section below.